Alosetron — Discount Pricing

Other medications in Digestive Health

• Bisacodyl
• Budesonide (Crohn)
• Certolizumab
• Cholestyramine (GI)
• Dexlansoprazole
• Docusate
• Eluxadoline
• Golimumab

About Alosetron

Alosetron is a specialized medication prescribed for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) who haven't responded to other treatments. It helps manage debilitating symptoms, improving quality of life. Understanding its role and how to access it affordably is crucial. TheDrugClub is dedicated to helping members like you find savings on important prescriptions such as alosetron.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Alosetron is approved for (FDA label)

Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with alosetron tablets, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of alosetron tablets in men.

Source: Read the full FDA label on DailyMed. Label effective date: April 1, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Alosetron (FDA label)

WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS Infrequent but serious gastrointestinal adverse reactions have been reported with the use of alosetron tablets. These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization, and rarely, blood transfusion, surgery, and death. Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have not responded adequately to conventional therapy [see Indications and Usage (1)] . Alosetron tablets should be discontinued immediately in patients who develop constipation or symptoms of ischemic colitis. Patients should immediately report constipation or symptoms of ischemic colitis to their prescriber. Alosetron tablets should not be resumed in patients who develop ischemic colitis. Patients who have constipation should immediately contact their prescriber if the constipation does not resolve after alosetron tablets is discontinued. Patients with resolved constipation should resume alosetron tablets only on the advice of their treating prescriber [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) , (5.2)]. WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS See full prescribing information for complete boxed warning. Infrequent but serious gastrointestinal adverse reactions have been reported with the use of alosetron tablets. These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization and, rarely, blood transfusion, surgery, and death.

Source: FDA prescribing information (DailyMed). Set ID: 38f5341f-5ae3-46bf-8bfc-30dff2068477. SPL document ID: cd337c95-1e5a-4dfa-84f7-e668c93d8565. Label effective date: April 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Alosetron (FDA label)

0.5 mg and 1 mg tablets Alosetron Tablets USP, 0.5 mg (0.562 mg alosetron HCl equivalent to 0.5 mg alosetron), are round, film-coated, white colored biconvex tablets debossed with "LS 702" on one side and plain on other side. Alosetron Tablets USP, 1 mg (1.124 mg alosetron HCl equivalent to 1 mg alosetron), are round, film-coated, blue colored biconvex tablets debossed with "LS 701" on one side and plain on other side. Tablets: 0.5 and 1 mg

Source: FDA prescribing information (DailyMed). Set ID: 38f5341f-5ae3-46bf-8bfc-30dff2068477. SPL document ID: cd337c95-1e5a-4dfa-84f7-e668c93d8565. Label effective date: April 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Alosetron (FDA label)

The following adverse reactions are described in more detail in other sections of the label: Complications of constipation [see Boxed Warning , Warnings and Precautions ( 5.1 )] Ischemic colitis [see Boxed Warning , Warnings and Precautions ( 5.2 )] Most common adverse reactions (incidence >2% and >placebo) in clinical studies were constipation, abdominal discomfort and pain, nausea and gastrointestinal discomfort and pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 38f5341f-5ae3-46bf-8bfc-30dff2068477. SPL document ID: cd337c95-1e5a-4dfa-84f7-e668c93d8565. Label effective date: April 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.